Where Will TJX Companies Stock Be in 10 Years?
Off-price retail is as popular as ever thanks to social…
Buy
67
CDXS Quote, Financials, Valuation and Earnings
Last price:
$5.00
Seasonality move
:
-2.42%
Day range:
$4.85 - $5.07
52-week range:
$2.53 - $6.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.47x
P/B ratio:
5.54x
Volume:
638.7K
Avg. volume:
806.4K
1-year change:
86.57%
Market cap:
$406.9M
Revenue:
$70.1M
EPS (TTM):
-$0.87
Analysts' Opinion
-
Consensus RatingCodexis has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.50, Codexis has an estimated upside of 50% from its current price of $5.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $5.00.
Fair Value
-
According to the consensus of 6 analysts, Codexis has 50% upside to fair value with a price target of $7.50 per share.
CDXS vs. S&P 500
-
Over the past 5 trading days, Codexis has overperformed the S&P 500 by 10.67% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Codexis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Codexis has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Codexis reported revenues of $12.8M.
Earnings Growth
-
Codexis has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Codexis reported earnings per share of -$0.29.
Enterprise value:
345.3M
EV / Invested capital:
--
Price / LTM sales:
5.47x
EV / EBIT:
--
EV / Revenue:
5.36x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-7.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$49M
Return On Assets:
-43.07%
Net Income Margin (TTM):
-96.35%
Return On Equity:
-79.15%
Return On Invested Capital:
-65.04%
Operating Margin:
-129.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $132.7M | $74M | $64.4M | $9.3M | $12.8M | |
| Gross Profit | $96.3M | $55.6M | $49M | $7M | $8.5M | |
| Operating Income | -$32M | -$65.2M | -$50.7M | -$18.9M | -$16.6M | |
| EBITDA | -$22.6M | -$65.6M | -$31M | -$28.5M | -$13.7M | |
| Diluted EPS | -$0.48 | -$1.20 | -$0.87 | -$0.50 | -$0.29 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $102.9M | $174.1M | $146M | $103M | $112.9M | |
| Total Assets | $138M | $227.6M | $235.3M | $154.5M | $148.2M | |
| Current Liabilities | $20.5M | $33.5M | $31.9M | $38.4M | $35.1M | |
| Total Liabilities | $47.2M | $58.5M | $81.2M | $62.9M | $74.8M | |
| Total Equity | $90.8M | $169.1M | $154.1M | $91.5M | $73.4M | |
| Total Debt | -- | -- | -- | -- | $28.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7M | -$36.7M | -$44M | -$16.3M | -$13M | |
| Cash From Investing | -$19.1M | -$5.9M | -$53M | -$1.1M | $1.5M | |
| Cash From Financing | $1.5M | $8.5M | $59.4M | -$108K | $30.3M | |
| Free Cash Flow | -$6.8M | -$41.4M | -$46.1M | -$17M | -$14M | |
CDXS
Sector
Market Cap
$406.9M
$44.9M
Price % of 52-Week High
82.24%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
-14.78%
-0.75%
1-Year Price Total Return
86.57%
-33.54%
Beta (5-Year)
2.131
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.75
200-day SMA
Buy
Level
$3.55
Bollinger Bands (100)
Buy
Level
2.97 - 4.83
Chaikin Money Flow
Sell
Level
-6.5M
20-day SMA
Buy
Level
$4.92
Relative Strength Index (RSI14)
Buy
Level
53.10
ADX Line
Buy
Level
17.31
Williams %R
Neutral
Level
-39.9209
50-day SMA
Buy
Level
$4.74
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
25.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.8435)
Sell
CA Score
(Annual)
Level (-1.15)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.1691)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
Stock Forecast FAQ
In the current month, CDXS has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CDXS average analyst price target in the past 3 months is $7.50.
-
Where Will Codexis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Codexis share price will rise to $7.50 per share over the next 12 months.
-
What Do Analysts Say About Codexis?
Analysts are divided on their view about Codexis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Codexis is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Codexis's Price Target?
The price target for Codexis over the next 1-year time period is forecast to be $7.50 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CDXS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Codexis is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDXS?
You can purchase shares of Codexis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Codexis shares.
-
What Is The Codexis Share Price Today?
Codexis was last trading at $5.00 per share. This represents the most recent stock quote for Codexis. Yesterday, Codexis closed at $5.00 per share.
-
How To Buy Codexis Stock Online?
In order to purchase Codexis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will CVS Health Stock Recover?
It’s been a treacherous journey for CVS Health Corporation (NYSE:CVS)…
Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 16
Quantum [QMCO] is down 0% over the past day.
Buy
51
QRVO alert for Jan 16
Qorvo [QRVO] is down 0% over the past day.
Sell
31
ATEX alert for Jan 16
Anterix [ATEX] is down 0% over the past day.
